张勇,郭宁

• 1:西安交通大学第一附属医院心内科

摘要(Abstract)：

<正>心血管疾病(cardiovascular disease,CVD)是严重的非传染性疾病之一。2017年全球CVD总死亡人数已达1779万,居非传染性疾病首位[1]。近年来,我国CVD患病率仍处于持续上升阶段。2016年CVD死亡率仍居首位,农村和城市CVD死亡占全部死因的比率分别为45.50%和43.16%[2]。虽然CVD的形势严峻,但可以预防,尤其是在冠心病(coronary artery disease,CAD)等的危症人群中,有效的二级预防是减少复发与死亡、提高患者生存质量的重要手段[2]。目前多个指南都认可和优先推荐血小板腺苷二磷酸(adenosine diphosphate,ADP)受体P2Y12的抑制剂作为CVD患者双联抗血小板治疗(dual antiplatelet therapy,DAPT)

关键词(KeyWords)： 替格瑞洛;长期应用;心血管事件;二级预防

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张勇,郭宁

参考文献(References)：

• [1] Roth GA, Abate D, Abate KG, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195countries and territories, 1980-2017:a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159):1736-1788.
• [2]中国心血管病预防指南（2017）写作组，中华心血管病杂志编辑委员会.中国心血管病预防指南（2017）.中华心血管病杂志，2018,46(1):10-25.
• [3] Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines:an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of st-elevation myocardial infarction,2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation,2016, 134(10):e123-e155.
• [4] Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Kardiol Pol, 2017, 75(12):1217-1299.
• [5] Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC). Eur Heart J, 2018, 39(2):119-177.
• [6] Sousa-Uva M, Neumann FJ, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur J Cardiothorac Surg,2019, 55(1):4-90.
• [7] Dobesh PP, Oestreich JH. Ticagrelor:pharmacokinetics,pharmacodynamics, clinical efiicacy, and safety. Pharmacotherapy,2014, 34(10):1077-1090.
• [8] Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory eff ects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes:the PLATO(PLATelet inhibition and patient Outcomes)PLATELET substudy. J Am Coll Cardiol,2010, 56(18):1456-1462.
• [9] Teng R, Butler K. Pharmacokinetics, pharmacodynamics,tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12)receptor antagonist, in healthy subjects. Eur J Clin Pharmacol, 2010, 66(5):487-496.
• [10] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009, 361(11):1045-1057.
• [11] Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:the task force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC). Eur Heart J, 2011, 32(23):2999-3054.
• [12] Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med, 2015,372(19):1791-1800.
• [13] Furtado RHM,Nicolau JC, Magnani G,et al. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting:insights from PEGASUS-TIMI54. Eur Heart J,2019.[Epub ahead of print].
• [14] Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med, 2019, 381(14):1309-1320.
• [15] Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention(THEMIS-PCI):a phase 3,placebo-controlled, randomised trial. Lancet, 2019, 394(10204):1169-1180.
• [16] Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med, 2019, 381(21):2032-2042.
• [17]中国医师协会急诊医师分会，国家卫健委能力建设与继续教育中心急诊学专家委员会，中国医疗保健国际交流促进会急诊急救分会.急性冠脉综合征急诊快速诊治指南（2019）.临床急诊杂志，2019,20(4):253-262.
• [18]中华医学会心血管病学分会介入心脏病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南（2016）.中华心血管病杂志，2016, 44(5):382-400.
• [19]中国老年学学会心脑血管病专业委员会，中国康复医学会心脑血管病专业委员会.稳定性冠心病口服抗血小板药物治疗中国专家共识.中华心血管病杂志，2016, 44(2):104-111.
• [20]中国医师协会心血管内科医师分会血栓防治专业委员会，中华医学会心血管病学分会介入心脏病学组，中华心血管病杂志编辑委员会.替格瑞洛临床应用中国专家共识.中华心血管病杂志，2016,44(2):112-120.
• [21]王江友，苏晞.冠状动脉支架置入后双联抗血小板治疗时限的研究和临床决策.中国介入心脏病学杂志，2016,24(3):160-165.
• [22]崔炜.解读最新证据：再议双联抗血小板治疗持续时间问题.中国介入心脏病学杂志，2015, 23(3):173-176.
• [23] Gao F, Shen H, Wang ZJ, et al. Rationale and design of the RTAF study:Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention. Contemp Clin Trials, 2015, 43:129-132.